

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients

Flaminia Olearo^{1*}, Huyen Nguyen^{2,3*}, Fabrice Bonnet^{4,5}, Sabine Yerly⁶, Gilles Wandeler⁷,
Marcel Stoeckle⁸, Matthias Cavassini⁹, Alexandra Scherrer^{2,3}, Dominique Costagiola¹⁰,
Patrick Schmid¹¹, Huldrych F Günthard^{2,3}, Enos Bernasconi¹², Jürg Boeni³, Antonella
D'Arminio Monforte¹³, Maurizio Zazzi¹⁴, Barbara Rossetti¹⁵, Didier Neau⁵, Pantxika
Bellecave¹⁶, Bart Rijnders¹⁷, Peter Reiss¹⁷, Ferdinand Wit¹⁷, Roger Kouyos^{2,3**}, Alexandra
Calmy^{1**}

* *Flaminia Olearo and Huyen Nguyen contributed equally to this manuscript.*

** *Alexandra Calmy and Roger Kouyos contributed equally to this manuscript.*

1 Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine,
Geneva, Switzerland

2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
Zurich, Switzerland

3 Institute of Medical Virology, Swiss National Reference Centre for Retroviruses,
University of Zurich, Zurich, Switzerland

4 Univ. Bordeaux, ISPED, INSERM U1219, F33000 Bordeaux, France

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

5 CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, F33000

Bordeaux, France

6 Laboratory of Virology, Geneva University Hospitals and Faculty of Medicine, Geneva,

Switzerland

7 Institute of Social and Preventive Medicine, University Hospital of Bern, Bern,

Switzerland.

8 Division of Infectious Diseases, University Hospital of Basel, Basel, Switzerland

9 Division of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland

10 NSERM, Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France

11 Division of Infectious Diseases and Hospital Epidemiology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland

12 Division of Infectious Diseases, Ospedale Regionale di Lugano, Lugano, Switzerland

13 Department of Health Sciences, Institute of Infectious and Tropical Medicine, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

14 Department of Medical Biotechnology, University of Siena, Siena, Italy

15 Infectious Diseases Unit, AOU Senese, Siena, Italy

16 Virology Laboratory, CHU de Bordeaux, Bordeaux, France

17 Department of Internal Medicine, Section of Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands

Key words: ABC/3TC/DTG, virological failure, M184V/I, treatment-experienced patients.

Corresponding Author:

Flaminia Olearo, MD

Division of Infectious Diseases

Geneva University Hospitals

4 Rue Gabrielle-Perret-Gentil

1211 Geneva 14 / Switzerland

E-mail: flaminiaolearo@hotmail.com; tel.: 0049 1738 815647

Alternative Corresponding author:

Professor Alexandra Calmy

Division of Infectious Diseases

Geneva University Hospitals

4 Rue Gabrielle-Perret-Gentil

1211 Geneva 14 / Switzerland

E-mail: Alexandra.Calmy@hcuge.ch; tel.: 0041 (0)22 372 95 99

Study summary

In ART-experienced patients on abacavir/lamivudine/dolutegravir, we observed few virological failures and found no evidence for an impact of previously-acquired M184V/I mutation on this outcome. Additional analyses are required to demonstrate whether these findings will remain robust during a longer follow-up.

ABSTRACT

Background. The impact of the M184V/I mutation on the virological failure (VF) rate in HIV-positive patients with suppressed viremia switching to an abacavir/lamivudine/dolutegravir regimen has been poorly evaluated.

Methods. Observational study from five European HIV cohorts among treatment-experienced adults with ≤ 50 copies/mL of HIV-1 RNA who switched to abacavir/lamivudine/dolutegravir. Primary outcome was the time to first VF (two consecutive HIV-1 RNA > 50 copies/mL or single HIV-1 RNA > 50 copies/mL accompanied by change in ART). We also analyzed a composite outcome considering the presence of VF and/or virological blips. We report also the results of an inverse probability weighting (IPW) analysis on a restricted population with a prior history of VF on any ART regimen to calculate statistics standardized to the disparate sampling population.

Results: We included 1626 patients (median follow-up, 288.5 days [IQR, 154-441]). Patients with a genotypically documented M184V/I mutation (n=137) had a lower CD4 nadir and a longer history of antiviral treatment. The incidence of VF was 29.8 (11.2-79.4) per 1000 person-years in those with a previously documented M184V/I, and 13.6 (8.4-21.8) in patients without documented M184V/I. Propensity score weighting in a restricted population (n=580) showed that M184V/I was not associated with VF or the composite endpoint (HR 1.27 [95% CI 0.35-4.59]; HR 1.66 [95% CI 0.81-3.43], respectively).

Conclusions: In ART-experienced patients switching to an abacavir/lamivudine/dolutegravir treatment, we observed few VFs and found no evidence for an impact of previously-acquired M184V/I mutation on this outcome. Additional analyses are required to demonstrate whether these findings will remain robust during a longer follow-up.

INTRODUCTION

Integrase strand transfer inhibitors have been widely prescribed and represent the preferred first-line antiretroviral regimen in most major guidelines for human immunodeficiency virus (HIV)-positive patients [1,2]. In combination with two nucleoside reverse transcriptase inhibitors (NRTIs), dolutegravir (DTG) was found to be superior to boosted protease inhibitors (PI/r) or a non-nucleoside NRTI-based regimen in large clinical trials [3,4]. DTG has also been very effective in treatment-experienced patients due to its high resistance barrier [5,6]. More recently, a randomized trial of rilpivirine-DTG dual therapy in treatment-experienced patients was shown to be non-inferior for the maintenance of viral suppression when compared to continuing conventional three-drug combination antiretroviral regimens [7]. However, the initial enthusiasm regarding the widespread use of DTG has been tempered by a number of factors, including side-effects such as neuropsychiatric disturbances, emergent resistance when given in monotherapy, and possible teratogenicity in early pregnancy [8–10]. Although DTG monotherapy was found to be non-inferior to combination antiretroviral therapy (ART) in the first 24 weeks, virological failure (VF) occurred thereafter and led to the emergence of DTG resistance [9]. Similar results have been found in the DOLAM trial where a higher risk of VF was observed with DTG monotherapy compared with dual 3TC/DTG and triple ART [11]. At present, DTG is not recommended as maintenance monotherapy [12]. However, its use in monotherapy was shown to be effective in patients conventionally treated during primary HIV infection and in whom treatment was thereafter simplified to DTG monotherapy [13].

While DTG uptake has occurred at an unprecedented pace, the impact of past NRTI mutations in treatment-experienced patients switching to an abacavir (ABC)/3TC/DTG

regimen has been only partially explored. Furthermore, the 2015 changes in the French National Agency for AIDS Research resistance algorithms [14] highlighted the risk of the impaired efficacy of ABC in the presence of the M184V/I mutation, as previously observed for 3TC. Thus, the clinical decision to switch to an ABC/3TC/DTG regimen could be influenced by a patient having evidence of harboring a M184V/I mutation, which leads to 3TC resistance and may potentially impair the effectiveness of both 3TC and, to a lesser extent ABC, thus resulting in a treatment representing functional DTG monotherapy.

We conducted a prospective study using data from five large HIV cohorts in four European countries (France, Italy, The Netherlands and Switzerland) to assess the efficacy of the ABC/3TC/DTG regimen in virologically-suppressed, ART-experienced patients, with or without a previously documented M184V/I mutation.

METHODS

Study Design

We conducted an observational longitudinal analysis of prospectively collected data from five different HIV European cohorts: ANRS-CO3 Aquitaine for HIV-positive French patients [15]; Antiviral Response Cohort Analysis (ARCA) containing data on HIV resistance in Italy [16]; AIDS Therapy Evaluation in The Netherlands (ATHENA) [17]; the Italian Cohort of Antiretroviral-Naïve Patients (ICONA) [18]; and the Swiss HIV Cohort Study (SHCS) [19]. All patients provided informed consent for the use of their clinical and laboratory data for research purposes according to country-specific requirements. Data from the different sources were exchanged and pooled according to the HIV Cohorts Data Exchange Protocol standard in a pseudonymised form in compliance with national ethical principles and privacy legislation governing the individual cohorts [20].

Patient Selection

Observations spanned from when DTG became available in each cohort country (16 January 2014 in The Netherlands, 1 May 2014 in France, 8 May 2014 in Switzerland, and 10 October 2014 in Italy) until February 2018. Eligible patients were 18 years of age or older, treatment-experienced HIV patients with least one resistance profile available before the start of the ABC/3TC/DTG regimen, a plasma HIV-1 RNA level ≤ 50 copies/mL at the time of the switch, and at least one HIV RNA assessment following the start of the ABC/3TC/DTG regimen. The selection process was conducted by each cohort according to the inclusion criteria and the cohort-specific data were then transferred to the SHCS to be merged and analysed. Patients with a follow-up of less than 30 days and those with missing data for the primary outcome were excluded from the analysis.

Virological Characteristics

The presence of M184V/I mutations was established by the cumulative resistance profile available before the switch to ABC/3TC/DTG, including resistance tests performed before any treatment was started for a fraction of patients. Information on thymidine analogue mutations (TAMs: M41L, D67N, K70R, L210W, T215Y/F and K219Q/E) before the switch to ABC/3TC/DTG was also obtained.

Endpoints

The primary objective was to explore the effectiveness of ABC/3TC/DTG among treatment-experienced patients with or without a documented M184V/I mutation. VF was defined as two consecutive HIV-1 RNA measurements >50 copies/mL or a single HIV-RNA value >50 copies/mL accompanied by a change in ART or censoring, whichever occurred first.

As a secondary objective, we considered a composite outcome combining VF with virological blip/s (VBs), defined as isolated detectable HIV-1 RNA measurements >50 copies/mL followed by a viral load (VL) <50 copies/ml.

The following factors were explored as predictors of VF and/or VBs: age; sex; body mass index; ethnicity; VL before the first ART regimen above or below 100,000 copies/mL; CD4 count nadir; CD4 count at the time of the switch to ABC/3TC/DTG; number of TAMs from pre-ABC/3TC/DTG genotypes; prior VFs; years of HIV infection; HIV transmission route; intravenous drug use; HIV infection stage; duration of viral suppression before the switch to ABC/3TC/DTG; and previous PI or integrase inhibitor exposure.

Data Analysis

Kaplan Meier plots/estimators and unweighted and inverse probability weighted (IPW) univariate Cox proportional-hazard models were used to assess the primary and secondary outcomes [21,22]. To calculate the weights, we used multivariate logistic regression modelling of the likelihood of a patient having the M184V/I mutation to calculate the propensity score ($\hat{e}(x)$), which indicates the calculated probability of each patient having the M184V/I mutation based on the following confounders: age; sex; body mass index; race; VL before the first antiretroviral regimen above or below 100,000 copies/mL; CD4 nadir; number of TAMs from pre-ABC/3TC/DTG genotypes; transmission route; years of HIV infection; months of viral suppression before the switch to ABC/3TC/DTG; and previous protease or integrase inhibitor exposure. The propensity scores were then converted to the inverse proportional weights where the weight was set as equal to $1/\hat{e}(x)$ for individuals with M184V/I and $1/[1 - \hat{e}(x)]$ for individuals without the mutation [22]. As initial attempts at the weighting procedure yielded two groups that were exceedingly heterogenous (Figure 1S), we

performed the final weighted analysis only on the subpopulation of the 580 patients who had failed on an ART regimen prior to ABC/3TC/DTG initiation, with and without a documented M184V/I mutation.

With regards to the propensity score distributions, we observed an improved overlap between the M184V/I and non-M184V/I population when restricted to those with previous VF, which led to a convergence in their characteristics (Figure 1S, Table S1).

As recommended for weighted survival analyses, the confidence intervals were calculated using robust variance estimations [23,24].

The secondary objectives were assessed with categorical variables analyzed by the Chi-square or Fisher's exact test, as appropriate, and continuous variables by the Student's t-test or Mann-Whitney test, depending on data distribution. Time-at-risk started with the switch to ABC/3TC/DTG and ended at the time of the penultimate VL measurement where the second reading may occur up to 6 months after discontinuation of the ABC/3TC/DTG regimen or first VF.

A sensitivity analysis was performed by excluding individuals who modified ABC/3TC/DTG treatment because of drug-related adverse events. Statistical significance was set at a p value <0.05. Statistical analysis was performed using R version 3.3.1 (21 June 2016) (RStudio: Integrated Development for R.R Studio, Inc, Boston, MA).

RESULTS

Baseline and Patient Characteristics

Table 1 shows the characteristics of one thousand six hundred and twenty-six patients were included in the analysis: 778 (47.8%) from SHCS; 460 (28.3%) from ATHENA; 168 (10.3%) from the Aquitaine cohort; 132 (8.2%) from ICONA; and 88 (5.4%) from ARCA. The

highest prevalence of the M184V/I mutation was found in the Aquitaine cohort (37 patients; 22.0%), followed by ARCA (14 patients; 15.9%), SHCS (56 patients; 7.2%), ATHENA (24 patients; 5.2%) and ICONA (6 patients; 4.5%). Overall, 137 patients had an M184V/I mutation (8.4%) with a ratio of the presence/absence of the M184V/I mutation of approximately 1:11. Median follow-up was 288.5 days (interquartile range, 154-441). Patients with M184V/I were predominantly male, with a mean age of 53.3 years. They had a longer duration of HIV infection, ART treatment and a longer virological suppression before the switch to ABC/3TC/DTG compared to patients without the M184V/I mutation. Most patients with a M184V/I mutation had experienced VF during their previous treatment history (127; 92.7%) compared to those without the mutation (453; 30.4%).

Virological Failures

We observed 21 (1.29%) VFs among the 1626 patients included in the study. Among these, 17 (1.21%) patients had no previously detected M184V/I mutation and 4 (3%) did (Table 2). Seventy-five patients had a VB; 63 (4.2%) and 12 (8.8%) in patients without and with a M184V/I mutation, respectively (mean HIV-RNA level, 181 [92-269] and 267 [28-563]). The incidence of VF after the switch to ABC/3TC/DTG was 29.8 (11.2-79.4) and 13.6 (8.4-21.8) per 1000 person-years in patients with and without M184V/I, respectively. The rate difference was 16.4 (-13.7 to 46.2; $p=0.09$). Among the six patients with a genotype available after the VF, no new mutations were observed. Genotypic testing was not performed in 13 patients because the low VL was followed by an undetectable VL, and information was missing for the remaining two patients (Table S2).

Risk Factor Analysis (VF)

In the univariate Cox proportional-hazards analyses, the presence of the M184V/I mutation was not significantly associated with a higher risk of failure (hazard ratio [HR]: 1.81; 95% CI: 0.60-5.49; $p=0.29$; Figure 1a).

Composite Outcome: Occurrence of VF and/or VBs

VF and/or VBs were observed in 15/137 (10.95%) patients with a documented M184V/I mutation compared to 73/1489 (4.9%) patients in the group with a wild type at this position. The unweighted univariate analysis showed that M184V/I had an effect on the increase of the risk of the composite outcome (HR: 1.92; 95% CI: 1.09-3.35; $p=0.022$; Figure 2a). However, the propensity score on the total study population was not statistically significant (HR: 1.66; 95% CI: 0.93-2.96).

IPW-Adjusted Analysis on a Restricted Population (Patients with Prior VF)

To fulfil the prerequisites for the IPW-adjusted analysis, we only performed this particular analysis on the restricted population of 580 individuals who had experienced VF on an ART regimen prior to ABC/3TC/DTG, which led to a convergence of the population characteristics after IPW adjustment (Table 3). We observed 12 (2.1%) VFs among those with a previous VF before the switch to the ABC/3TC/DTG regimen. In this subpopulation, eight (1.8%) patients had no previous archived M184V/I mutation before IPW adjustment, while 4 (3.2%) did (Table 4). VF incidence was 32.0 (0.64-63.4) and 10.4 (0.21-20.60) for those with and without the M184V/I mutation, respectively. The rate difference was 21.7 (-11.4-54.6; $p=0.199$). The unweighted univariate analysis for the patients with prior VF was also similar (HR: 1.19; 95% CI: 0.35-4.06; $p=0.781$; Figure 1b).

In the IPW-adjusted analysis of 580 patients with prior VF, results for the primary and secondary outcomes were essentially unchanged, For the primary outcome, the estimated HR

for patients with the M184V/I mutation was 1.27 (95% CI: 0.35-4.59; $p=0.733$; Figure 1c) and for the composite outcome the estimated HR was 1.66 (95% CI: 0.81–3.43; $p=0.17$).

Thymidine Analogue Mutations (TAMs)

At least two TAMs were documented in 42.3% of patients with M184V/I compared to 3.3% of those without the mutation (Table S3). Among the 21 patients who experienced VF, two had three archived TAMs (D67N, K70R and K219Q/E and M41L, K70R and K219Q/E), including the M184V/I mutation. One patient had two TAMs (D67N and K219Q/E) without an archived M184V/I mutation. The remaining 18 patients had no archived TAMs.

Sensitivity Analysis

The sensitivity analysis was performed on 489 patients who had prior VF after excluding all those who stopped ABC/3TC/DTG due to drug-related adverse events. We did not observe any significant association between VF and the M184V/I mutation (data not shown). In the propensity weighted analysis, the HR was 1.61 (95% CI: 0.76 – 3.39; $p=0.22$).

DISCUSSION

To the best of our knowledge, this study is the largest observational study to focus on the impact of the M184V/I mutation on the risk of VF in virologically-suppressed patients switching to ABC/3TC/DTG. Overall, we observed a very low VF rate (1.3%) after the switch to ABC/3TC/DTG, with no statistically significant difference in the VF incidence among patients with or without M184V/I after correction for differences in patient characteristics. Furthermore, no new mutations were observed in reverse transcriptase or integrase after VF in any of the patients in which genotyping was successfully performed,

with the caveat that the genotypic resistance results were available for only a minority of patients (6/21).

One of the main strengths of our study is the use of an IPW-adjusted analysis for the population restricted to those with VF on a prior regimen [25]. In this multi-cohort study, the characteristics of the groups of patients with or without M184V/I were too divergent to allow the use of a standard multivariate Cox proportional-hazards analysis. We took into account several predictors of VF. Among these, the presence of TAMs was considered as one of the most relevant. We showed with the IPW analysis that the M184V/I mutation had no statistically significant effect on VF, including when using the composite outcome (although a trend could not be excluded). However, the wide confidence intervals observed and the limited follow-up should be taken into consideration when interpreting the clinical relevance of our findings. Furthermore, we cannot exclude residual confounding given the absence of data on treatment adherence. Indeed, precise information about adherence to ART was only available for a small part of the dataset and patients with or without emergence of the M184V/I mutation after VF may have had a different behaviour with regards to treatment adherence.

Previous studies have addressed the effect of the M184V/I mutation on the efficacy of a DTG-containing regimen. Although most were small trials (less than 500 patients) originating from single cohorts, they all described low VF rates, irrespective of the presence of the M184V/I mutation. In the study by Gagliardini et al [26], the three-year probability to remain VF-free among treatment-experienced patients on PI- or DTG-based dual therapy containing lamivudine in the presence or absence of the M184V/I mutation was 87.8% and 91.9%, respectively ($p=0.32$). Furthermore, among 126 patients treated with a 3TC/DTG-

containing regimen and followed for a median of 1.3 years, VF was detected in none of 21 patients with the M184V/I mutation and in 2 of 105 patients without the mutation. Marcelin et al [27] and Reynes et al [28] reported similar results. In both studies, no VF was detected in 59 and 27 patients, respectively, who switched to a DTG-based regimen, despite a high M184V/I prevalence (100% in the first study, 63% in the latter).

In a recent phase 3b, open-label, non-inferiority, randomized clinical trial of 627 patients, DTG was shown to be superior at 48 weeks compared to ritonavir-boosted lopinavir, plus two NRTIs in adults in whom previous first-line ART with a non-NRTI plus two NRTIs had failed [29]. Of note, M184V/I was present at baseline in more than 80% of patients and 3TC or FTC was included as part of the backbone in both arms of the trial. A recent subgroup analysis [30] of this study showed that the response rate of DTG was also high when 3TC or FTC was used in the presence of a M184V/I mutation. Similar results were found in more recent studies where DTG plus one to two NRTIs were non-inferior to PI-based therapy, regardless of the presence of the M184V/I mutation and other NRTI mutations at 48 [31] and 78 weeks [32].

Also other INSTIs, as elvitegravir in the co-formulation elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, showed in a prospective open-label study to be effective in maintaining viral suppression at week 12 despite archived M184V/I mutations[33].

An association between low-level viremia (considered as intermittent episodes of VBs) and subsequent VF, inadequate CD4 recovery, and the development of drug resistance have been demonstrated in a previous study [34–36]. More recently, Hermans et al [37] showed that VBs (defined as the occurrence of one viral load measurement of 51–999 copies per mL during ART, followed by virological suppression) might be associated with a 2.6-fold higher HR for VF. Similar results were shown by Young et al., where an increase of HR 1.09 of viral rebound was detected for every magnitude blip increase of 100 copies/ml in naïve

patients [38]. Our study is more comparable to the latter one in terms of the VF definition.

Although the unweighted univariate analysis showed that M184V/I had a significant effect on the increase of the risk of the composite outcome, including both VBs and VF, this effect was no longer statistically significant in the IPW analysis.

Our study has several limitations. First, despite the fact that our study used data from five cohorts, the number of patients who developed VF during follow-up was small overall. Of note, our VF definition was particularly conservative, considering that for 13 patients a genotypic testing was not performed due to a limited VL, followed by an undetectable VL. In these cases, we probably identified a low-level viremia more than a clinically relevant true VF. A longer follow-up and additional data from more patients are needed before more definite conclusions can be drawn. It is also likely that patients with NRTI mutations in these cohorts are those who were treated with less potent regimens in the early days of highly active ART and perhaps were less compliant. Finally, a so-called “indication bias” may have occurred as physicians tended to prescribe a single pill regimen in patients with documented resistant mutations only if they were confident about patient adherence.

In conclusion, in this large international prospective study, we found an extremely low rate of VF among treatment-experienced patients receiving an ABC/3TC/DTG regimen, irrespective of the presence of a M184V/I mutation. Additional analyses are required to demonstrate whether these findings will remain robust during an extended observation period.

Funding

This work was financed within the framework of the SHCS, supported by the Swiss National Science Foundation (grant #177499), by the SHCS project # 816 of the SHCS Research Foundation, and by the Yvonne Jacob Foundation (to HFG), by the clinical research priority program of the University of Zurich viral infectious diseases section (to HFG).

HN, paid to institution, entity: University of Zurich University Research Priority Program: Evolution in Action: From Genomes to Ecosystems (grant # U-702-26-01), ongoing; paid to institution: entity: Swiss National Science Foundation (grant # BSSG10_155851), ongoing.

The ATHENA cohort is managed by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment.

Accepted Manuscript

Acknowledgments

We acknowledge all members of **Aquitaine**: scientific committee of the ANRS CO3

Aquitaine cohort

F. Bonnet (principal investigator), L. Wittkop (methodologist); C. Cazanave, V. Gaborieau, M. Hessamfar, E. Lazaro, G. Le Moal, D. Malvy, P. Mercié, D. Neau, M.O. Vareil, I. Pellegrin, P. Blanco, ME Lafon, P. Bellecave, S. Bouchet, D. Breilh, D. Lacoste, S. Lawson-Ayayi, A. Gimbert, S. Desjardin, L. Lacaze-Buzy, V. Petrov-Sanchez, L. Marchand, A. Perrier, F. Le Marec, O. Leleux; participating clinical centers: Hôpital Saint André, CHU de Bordeaux, Médecine Interne et Maladies Infectieuses, (F. Bonnet, N. Bernard, D. Dondia, P. Duffau, I. Faure, M. Hessamfar, D. Lacoste, P. Mercié, P. Morlat, F. Paccalin, MC Pertusa, MA Vandenhende, E. Riebero, C. Rivoisy); Hôpital Pellegrin, CHU de Bordeaux, Maladies Infectieuses et Tropicales (C. Cazanave, FA. Dauchy, A. Desclaux, M. Dupon, H. Dutronc, D. Neau, D. Malvy, A. Ochoa, T. Pistone, MC. Receveur, G. Wirth); Hôpital Haut-Lévêque, CHU de Bordeaux, Médecine Interne et Maladies Infectieuses (C. Greib, E. Lazaro, JL. Pellegrin, JF. Viallard); Hôpital d'Agen, Médecine Interne (Y. Imbert, M. Thierry-Mieg, P. Rispal); Hôpital de Libourne, Médecine Interne (O. Caubet, H. Ferrand, S. Tchamgoué); Hôpital de Bayonne, Maladies Infectieuses (S. Farbos, MO. Vareil, H. Wille); Hôpital de Dax, Médecine Interne et Maladies Infectieuses (K. Andre, L. Caunegre, Y. Gerard, F. Osorio-Perez); Hôpital Saint-Cyr/Villeneuve sur Lot, Maladies Infectieuses (I. Chossat); Hôpital de Mont de Marsan, Médecine Interne et Maladies Infectieuses (G. Iles, Y. Gerard, M. Labasse-Depis, F. Lacassin); Hôpital d'Arcachon, Médecine Interne (A. Barret, C. Courtault); Hôpital de Périgueux, Médecine Interne et Maladies Infectieuses (N. Berthol, B. Cougoul, P. Lataste, J. Marie, N. Rouanes); Hôpital de Pau, Médecine Interne et Maladies Infectieuses (G. Dumondin, V. Gaborieau); Hôpital d'Orthez, Médecine Interne, (Y. Gerard); data collection: S. Delveaux, B. Uwamaliya, K. Zara, A. Pougetoux, F. Diarra, C. Hanapier,

MJ Blaizeau, M. Decoin, E. Lenaud, Sylvie Lawson-Ayayi; project team CMG-EC A. Perrier (data manager), F. Le Marec (statistician), O. Leleux (project leader).

We thank the patients enrolled in the **ARCA** cohort as well as the ARCA scientific board and the companies supporting the initiative.

We acknowledge all members of **ATHENA**: Academic Medical Centre of the University of Amsterdam (AMC-UvA): HIV treating physicians: M. van der Valk*, S.E. Geerlings, M.H. Godfried, A. Goorhuis, J.W. Hovius, T.W. Kuijpers, F.J.B. Nellen, DT. van der Poll, J.M. Prins, P. Reiss, H.J. M. van Vugt, W.J. Wiersinga, F.W.M.N. Wit. HIV nurse consultants: M. van Duinen, J. van Eden, A.M.H. van Hes, F.J.J. Pijnappel, A.M. Weijsenfeld. HIV clinical virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaier, B. Berkhout, M.T.E. Cornelissen, C.J. Schinkel, K.C. Wolthers. Admiraal De Ruyter Ziekenhuis, Goes: HIV treating physicians: M. van den Berge, A. Stegeman. HIV nurse consultants: S. Baas, L. Hage de Looff. HIV clinical virologists/chemists: B Wintermans, J Veenemans. Catharina Ziekenhuis, Eindhoven: HIV treating physicians: M.J.H. Pronk*, H.S.M. Ammerlaan. HIV nurse consultants: E.S. de Munnik. HIV clinical virologists/chemists: A.R. Jansz, J. Tjhie, M.C.A. Wegdam, B. Deiman, V. Scharnhorst. DC Klinieken Laresse - Hiv Focus Centrum: HIV treating physicians: A. van Eeden*, M. van der Valk. HIV nurse consultants: W. Brokking, M. Groot, L.J.M. Elsenburg. HIV clinical virologists/chemists: M. Damen, I.S. Kwa. ETZ (Elisabeth-TweeSteden Ziekenhuis), Tilburg: HIV treating physicians: M.E.E. van Kasteren*, A.E. Brouwer. HIV nurse consultants: R. van Erve, B.A.F.M. de Kruijf-van de Wiel, S.Keelan-Pfaf, B. van der Ven. Data collection: B.A.F.M. de Kruijf-van de Wiel, B. van de Ven. HIV clinical virologists/chemists: A.G.M. Buiting, P.J. Kabel, D.Versteeg. Erasmus MC, Rotterdam: HIV treating physicians: M.E. van der Ende*, H.I. Bax, E.C.M. van Gorp, J.L. Nouwen, B.J.A. Rijnders, C.A.M. Schurink, A. Verbon, T.E.M.S. de Vries-Sluijs, N.C. de Jong-Peltenburg. HIV nurse consultants: N. Bassant, J.E.A. van Beek, M.

Vriesde, L.M. van Zonneveld. Data collection: H.J. van den Berg-Cameron, J. de Groot, M. de Zeeuw-de Man. HIV clinical virologists/chemists: C.A.B. Boucher, M.P.G Koopmans, J.J.A van Kampen, S.D. Pas. Flevoziekenhuis, Almere: HIV treating physicians: J. Branger*, R.A. Douma. HIV nurse consultant: C.J.H.M. Duijf-van de Ven. HagaZiekenhuis, Den Haag: HIV treating physicians: E.F. Schippers*, C. van Nieuwkoop. HIV nurse consultants: J.M. van IJperen, J. Geilings. Data collection: G. van der Hut. HIV clinical virologist/chemist: N.D. van Burgel. HMC (Haaglanden Medisch Centrum), Den Haag: HIV treating physicians: E.M.S. Leyten*, L.B.S. Gelinck. HIV nurse consultants: S. Davids-Veldhuis, A.Y. van Hartingsveld, C. Meerkerk, G.S. Wildenbeest. HIV clinical virologists/chemists: E. Heikens. Isala, Zwolle: HIV treating physicians: P.H.P. Groeneveld*, J.W. Bouwhuis, A.J.J. Lammers. HIV nurse consultants: S. Kraan, A.G.W. van Hulzen, M.S.M. Kruiper. Data collection: G.L. van der Blik, P.C.J. Bor. HIV clinical virologists/chemists: P. Bloembergen, M.J.H.M. Wolfhagen, G.J.H.M. Ruijs. Leids Universitair Medisch Centrum, Leiden: HIV treating physicians: F.P. Kroon*, M.G.J. de Boer, H. Scheper, H. Jolink. HIV nurse consultants: W. Dorama, N. van Holten. HIV clinical virologists/chemists: E.C.J. Claas, E. Wessels. Maasstad Ziekenhuis, Rotterdam: HIV treating physicians: J.G. den Hollander*, K. Pogany, A. Roukens. HIV nurse consultants: M. Kastelijns, J.V. Smit, E. Smit, D. Struik-Kalkman, C. Tearno. Data collection: T. van Niekerk. HIV clinical virologists/chemists: O. Pontesilli. Maastricht UMC+, Maastricht: HIV treating physicians: S.H. Lowe*, A.M.L. Oude Lashof, D. Posthouwer. HIV nurse consultants: R.P. Ackens, K. Burgers, J. Schippers. Data collection: B. Weijenberg-Maes. HIV clinical virologists/chemists: I.H.M. van Loo, T.R.A. Havenith. MC Slotervaart, Amsterdam: HIV treating physicians: J.W. Mulder*, S.M.E. Vrouwenraets, F.N. Lauw. HIV nurse consultants: M.C. van Broekhuizen, D.J. Vlasblom. HIV clinical virologists/chemists: P.H.M. Smits. MC Zuiderzee, Lelystad: HIV treating physicians: S. Weijer*, R. El Moussaoui. HIV nurse consultant: A.S. Bosma. Medisch

Centrum Leeuwarden, Leeuwarden: HIV treating physicians: M.G.A.van Vonderen*, L.M. Kampschreur. HIV nurse consultants: K. Dijkstra, S. Faber. HIV clinical virologists/chemists: J Weel. Medisch Spectrum Twente, Enschede: HIV treating physicians: G.J. Kootstra*, C.E. Delsing. HIV nurse consultants: M. van der Burg-van de Plas, H. Heins. Noordwest Ziekenhuisgroep, Alkmaar: HIV treating physicians: W. Kortmann*, G. van Twillert*, R. Renckens. HIV nurse consultant and data collection: D. Ruiter-Pronk, F.A. van Truijen-Oud. HIV clinical virologists/chemists: J.W.T. Cohen Stuart, E.P. IJzerman, R. Jansen, W. Rozemeijer W. A. van der Reijden. OLVG, Amsterdam: HIV treating physicians: K. Brinkman*, G.E.L. van den Berk, W.L. Blok, P.H.J. Frissen, K.D. Lettinga W.E.M. Schouten, J. Veenstra. HIV nurse consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene, I.B. van der Meché, M. Spelbrink, A.J.M. Toonen, S. Wijnands. HIV clinical virologists: D. Kwa. Data collection: R. Regez (coordinator). Radboudumc, Nijmegen: HIV treating physicians: R. van Crevel*, M. Keuter, A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff, J. Hoogerwerf. HIV nurse consultants: K.J.T. Grintjes-Huisman, M. de Haan, M. Marneef. HIV clinical virologists/chemists: J. Rahamat-Langendoen, F.F. Stelma. HIV clinical pharmacology consultant: D. Burger. Rijnstate, Arnhem: HIV treating physicians: E.H. Gisolf*, R.J. Hassing, M. Claassen. HIV nurse consultants: G. ter Beest, P.H.M. van Bentum, N. Langebeek. HIV clinical virologists/chemists: R. Tiemessen, C.M.A. Swanink. Spaarne Gasthuis, Haarlem: HIV treating physicians: S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse consultants: L.M.M. van der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV clinical virologists/chemists: W.A. van der Reijden, R. Jansen, B.L. Herpers, D. Veenendaal. Medisch Centrum Jan van Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen. HIV nurse consultants: M. van Wijk. Universitair Medisch Centrum Groningen, Groningen: HIV treating physicians: W.F.W. Bierman*, M. Bakker, J. Kleinnijenhuis, E. Kloeze, Y. Stienstra, K.R. Wilting, M. Wouthuyzen-Bakker. HIV nurse

consultants: A. Boonstra, P.A. van der Meulen, D.A. de Weerd. HIV clinical virologists/chemists: H.G.M. Niesters, C.C. van Leer-Buter, M. Knoester. Universitair Medisch Centrum Utrecht, Utrecht: HIV treating physicians: A.I.M. Hoepelman*, J.E. Arends, R.E. Barth, A.H.W. Bruns, P.M. Ellerbroek, T. Mudrikova, J.J. Oosterheert, E.M. Schadd, M.W.M. Wassenberg, M.A.D. van Zoelen. HIV nurse consultants: K. Aarsman, D.H.M. van Elst-Laurijssen, I. de Kroon, C.S.A.M. van Rooijen. Data collection: M. van Berkel, C.S.A.M. van Rooijen. HIV clinical virologists/chemists: R. Schuurman, F. VerduynLunel, A.M.J. Wensing. VUmc, Amsterdam: HIV treating physicians: E.J.G. Peters*, M.A. van Agtmael, M. Bomers. HIV nurse consultants: M. Heitmuller, L.M. Laan. HIV clinical virologists/chemists: C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandembroucke Grauls. Coordinating centre: Director: P. Reiss. Deputy director: S. Zaheri. Data analysis: D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.M.N. Wit, T.S. Boender. Data management and quality control: M. Hillebregt, A. de Jong, T. Woudstra. Data monitoring: D. Bergsma, S. Grivell, R. Meijering, M. Raethke, T. Rutkens. Data collection: L. de Groot, M. van den Akker, Y. Bakker, M. Bezemer, A. El Berkaoui, J. Geerlinks, J. Koops, E. Kruijne, C. Lodewijk, E. Lucas, R. van der Meer, L. Munjishvili, F. Paling, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, L. van de Sande, M. Schoorl, E. Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, E.C. Witte. Patient registration: B. Tuk.

We acknowledge all members of the **ICONA**: board directors: A d'Arminio Monforte (President), A Antinori (Vice-President), M Andreoni, A Castagna, F Castelli, R Cauda, G Di Perri, M Galli, R Iardino, G Ippolito, A Lazzarin, GC Marchetti, G Rezza, F von Schloesser, P Viale. Scientific secretary: A d'Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti, CF Perno. Steering Committee : A Antinori, F Bai, C Balotta, A Bandera, S Bonora, M Borderi, A Calcagno, A Capetti, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, S Cicalini, A Cingolani, P

Cinque, A Cozzi-Lepri, A d'Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N Gianotti, A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G Madeddu, F Maggiolo, G Marchetti, L Monno, C Mussini, S Nozza, CF Perno, C Pinnetti, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, L Sarmati. Statistical and monitoring team: A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano', M Macchia, A Tavelli. Biological bank INMI: F Carletti, S Carrara, A Di Caro, S Graziano, F Petroni, G Prota, S Truffa. Participating physicians and centers: Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, E Milano (Bari); F Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelnuovo, C Minardi, E Quiros Roldan (Brescia); B Menzaghi, C Abeli (Busto Arsizio); B Cacopardo, B Celesia (Catania); J Vecchiet, K Falasca (Chieti); A Pan, S Lorenzotti (Cremona); L Sighinolfi, D Segala (Ferrara); P Blanc, F Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello (Genova); M Lichtner, S Vita, (Latina); P Bonfanti, C Molteni (Lecco); A Chiodera, P Milini (Macerata); G Nunnari, G Pellicanò (Messina); A d'Arminio Monforte, M Galli, A Lazzarin, G Rizzardini, M Puoti, A Castagna, ES Cannizzo, MC Moioli, R Piolini, D Bernacchia, S Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); C Migliorino, G Lapadula (Monza); V Sangiovanni, G Borgia, V Esposito, F Di Martino, I Gentile, V Rizzo (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, M Trizzino (Palermo); F Baldelli, E Schiaroli (Perugia); G Parruti, F Sozio (Pescara); G Magnani, MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R Cauda, A Cristaudo, V Vullo, R Acinapura, D Moschese, M Capozzi, A Mondì, A Cingolani, M Rivano Capparuccia, G Iaiani, A Latini, R Gagliardini, MM Plazzi, S Savinelli, A Vergori (Roma); M Cecchetto, F Viviani (Rovigo); G Madeddu, A De Vito(Sassari); B Rossetti, F Montagnani (Siena); A Franco, R Fontana Del Vecchio (Siracusa); D Francisci, C Di Giuli (Terni); P Caramello, G

Di Perri, S Bonora, GC Orofino, M Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza); G Starnini, A Ialungo (Viterbo).

We acknowledge all members of the **SHCS**: V Aubert, M Battegay, E Bernasconi, J Boni (chair of the resistance group), DL Braun, H Bucher, A Calmy, M Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer (chairman of the clinical and laboratory committee), CA Fux, HF Gunthard (president of the SHCS), D Haerry (deputy of “Positive Council”), B Hasse, HH Hirsch, M Hoffmann, I Hosli, C Kahlert, L Kaiser, O Keiser, T Klimkait, RD Kouyos, H Kovari, B Ledergerber, G Martinetti, B Martinez de Tejada, C Marzolini, KJ Metzner, N Muller, D Nicca, G Pantaleo, P Paioni, A Rauch (chairman of the scientific board), C Rudin (chairman of the mother & child sub-study), AU Scherrer (head of the data center), P Schmid, R Speck, M Stockle, P Tarr, A Trkola, P Vernazza, G Wandeler, R Weber, S Yerly. Data were gathered by the five Swiss university hospitals, two cantonal hospitals, 15 affiliated hospitals and 36 private physicians (<http://www.shcs.ch/180-health-care-providers>).

REFERENCES

1. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. *JAMA* **2018**; 320:379–396.
2. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available at: <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed 16 February 2019.
3. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet* **2014**; 383:2222–2231.
4. Sharon L, Walmsley, Antonio Antela, Nathan Clumeck, et al. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. *N Engl J Med* **2013**; 369:1807–18.
5. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. *Lancet* **2013**; 382:700–708.
6. Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. *J Antimicrob Chemother* **2015**; 70:1507–1512.
7. Llibre JM, Hung C-C, Brinson C et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. *Lancet Lond Engl* **2018**; 391:839–849.
8. Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. *Lancet HIV* **2017**; 4:e547–e554.
9. Hocqueloux L, Raffi F, Prazuck T, et al. Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial. *Clin Infect Dis* **2019**;
10. Black V, Schwartz SR. Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz. *Lancet HIV* **2018**; 5:e732–e736.
11. Blanco JL, Rojas J, Paredes R, et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. *J Antimicrob Chemother* **2018**; 73:1965–1971.
12. Ryom L, Boesecke C, Bracchi M, et al. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. *HIV Med* **2018**; 19:309–315.

13. Braun DL, Turk T, Tschumi F, et al. Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial. *Clin Infect Dis* 2019 Jan 2. doi: 10.1093/cid/ciy1131. [Epub ahead of print]
14. HIV French Resistance. Available at: <http://www.hivfrenchresistance.org/>.
15. Collin A, Le Marec F, Vandenhende M-A, et al. Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000-2012. *PloS One* **2016**; 11:e0152970.
16. Modica S, Rossetti B, Lombardi F, et al. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. *HIV Med* **2019**; 20:137–146.
17. Boender TS, Smit C, van Sighem A, et al. AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile. *BMJ Open* **2018**; 8. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169757/>. Accessed 7 April 2019.
18. Fondazione Icona. Available at: http://www.fondazioneicona.org/_new2/.
19. The Swiss HIV Cohort Study. Cohort Profile: The Swiss HIV Cohort Study. *Int J Epidemiol* **2010**; 39:1179–1189.
20. HICDEP. <https://chip.dk/Tools-Standards/HICDEP>.
21. Potard V, Simon A, Lacombe J-M, Parienti J-J, Costagliola D, French Hospital Database on HIV (FHDH-ANRS CO4). Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4). *Clin Infect Dis* **2016**; 63:1254–1261.
22. Antonio Olmos, Priyalatha Govindasamy. A Practical Guide for Using Propensity Score Weighting in R. *Pract Assessment Res Eval* **2015**; 20(13):1-8.
23. Ashley L. Buchanan, Micheal G. Hudgens, Stephen R. Cole, Bryan Lau, Adaora A. Adimora. Worth the weight: using inverse probability weighted Cox models in AIDS research. *AIDS Res Hum Retroviruses* **2014**; 30:1170–1177.
24. Stephen R. Cole, Miguel A. Hernan. Constructing Inverse Probability Weights for Marginal Structural Models. *Pract Epidemiol* **2008**; 168: 656-664.
25. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. *Am J Epidemiol* **2006**; 163:262–270.
26. Gagliardini R, Ciccullo A, Borghetti A, et al. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. *Open Forum Infect Dis* **2018**; 5:ofy113.

27. Marcelin A, Charpentier C, Wirden M, et al. M184V/I as unique NRTI resistance mutation does not impact the efficacy of an abacavir/lamivudine/dolutegravir use as switch in patients with a fully suppressed viral load. In: 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 7 – 9 June 2017, Rome, Italy. Abstract 50.
28. Reynes J, Meftah N, Montes B. Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment-experienced HIV-infected patients: 48-week results from a pilot study (DOLULAM). In: Abstracts from the International Congress of Drug Therapy in HIV Infection, Glasgow, UK, 23-26 October 2016. Abstract 080.
29. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. *Lancet Infect Dis* **2019**; 19:253–264.
30. Danae Brown, Ruolan Wang, Mark Underwood, et al. DTG VS LPV/R (DAWNING): Efficacy by baseline NRTI resistance and second -line NRTI use. Conference on Retroviruses and Opportunistic Infections (CROI), 4-7 March 2019, Seattle, WA, USA, Abstract 144.
31. Chen G-J, Sun H-Y, Chang S-Y, et al. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse-transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. *Int J Antimicrob Agents* **2019**; 54:35-42.
32. Sörstedt E, Carlander C, Flamholc L, et al. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. *Int J Antimicrob Agents* **2018**; 51:733–738.
33. I. Perez Valero, J.M. Llibre, A. Lazzarin, et al. A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824). International AIDS Society, 23-27 July 2018, Amsterdam, The Netherlands. Abstract B38.
34. Swenson LC, Min JE, Woods CK, et al. HIV Drug Resistance Detected During Low-Level Viremia Is Associated with Subsequent Virologic Failure. *AIDS* **2014**; 28:1125–1134.
35. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. *HIV Med* **2006**; 7:437–441.
36. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. *AIDS* **2004**; 18:981–989.
37. Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. *Lancet Infect Dis* **2018**; 18:188–197.

38. Young J, Rickenbach M, Calmy A, et al. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. *BMC Infect Dis* **2015**; 15:382.

Accepted Manuscript

Table 1. Baseline Characteristics of Patients With or Without an Archived M184V/I Mutation.

Baseline characteristics			
Variables	Without M184V/I (N=1489)	With M184V/I (N=137)	p value
Follow up* (days)	307 (95% CI: 298-317)	358 (95% CI: 321-394)	0.010
Age, years *	48.5 (95% CI: 47.9-49.0)	53.3 (95% CI 51.6-55.0)	<0.001
Sex, female	319 (21.4%)	42 (30.7%)	0.017
BMI, kg/m ² *	24.0 (95% CI: 23.6-24.3)	23.5 (95% CI 22.7-24.2)	0.230
Time since documented HIV infection* (years)	10.6 (95% CI: 10.2-10.9)	20.2 (95% CI: 19.2-21.3)	<0.001
Time since ART initiation* (years)	8.5 (95% CI: 8.2-8.8)	17.3 (95% CI: 16.5-18.2)	<0.001
Viral suppression before the switch to ABC/3TC/DTG* (months)	83.5 (95% CI: 82.5-88.1)	134.0 (95% CI: 126.5-141.5)	<0.001
Patients with a previous documented VF	453 (30.4%)	127 (92.7%)	<0.001
CD4 T-cell count nadir *(mm ³)	232 (95% CI: 224-241)	178 (95% CI: 155-201)	<0.001
CD4 T-cell count at the time of the switch to ABC/3TC/DTG* (mm ³)	665 (95% CI: 649-680)	667 (95% CI: 612-722)	0.929

Viral Load before 1 st ART regimen*(copies/ml, log10 transformed)	4.84 (95% CI: 4.79-4.89)	4.77 (95% CI: 4.54-5.00)	0.576
Prior AIDS diagnosis	277 (18.6%)	38 (27.7%)	0.005
At least 2 TAMs	49 (3.3%)	58 (42.3%)	<0.001
At least 3 TAMs	29 (1.9%)	41 (29.9%)	<0.001
Distribution of M184V/I by cohort			<0.001
Aquitaine	131 (8.8%)	37 (27.0%)	
ARCA	74 (5.0%)	14 (10.2%)	
ATHENA	436 (29.3%)	24 (17.5%)	
ICONA	126 (8.5%)	6 (4.4%)	
SHCS	722 (48.5%)	56 (40.9%)	
Treatment class before the switch to ABC/3TC/DTG (at any time)			
NNRTI	897 (60.2%)	111 (81.0%)	<0.001
INSTI	282 (18.9%)	25 (18.2%)	0.933
PI	1082 (72.7%)	133 (97.1%)	<0.001

Mean*, IPW: inverse probability weighting analysis; CI: confidence interval; TAM: thymidine analogue mutations; NNRTI: non-nucleoside reverse transcriptase inhibitors; INSTI: integrase strand transfer inhibitors; PI: protease inhibitor.

Table 2. Virological Primary Outcomes of Patients With or Without M184V/I Mutations Archived in overall population

Outcomes	Primary Outcomes (Overall Population)		
	Without M184V/I (N=1489)	With M184V/I (N=137)	<i>p</i> value
Virological failure (VF)	17 (1.21%)	4 (3%)	0.09
- 2x HIV-RNA >50 copies/mL	10	1	
- 1x HIV-RNA >50 copies/mL + ABC/3TC/DTG stop	7	3	
Treatment (ABC/3TC/DTG) discontinued for reasons other than VF	232 (15.6%)	14 (10.2%)	0.12
Virological blips (VB)			
- at least 1 VB during ABC/3TC/DTG treatment	63 (4.2%)	12 (8.8%)	0.03
- mean copies/ml (95% CI)	181 (92-269)	267 (-28-563)	0.55
Incidence of VF per 1000 person-years	13.6 (8.4-21.8)	29.8 (11.2-79.4)	0.09

Table 3. Baseline Characteristics of Patients with Virological Failure on Prior Treatment, With or Without Archived M184V/I Mutations, Before and After Inverse Probability Treatment Weighted Adjustment.

Baseline characteristics					
Variables	Before IPW Adjustment			After IPW Adjustment	
	Without M184V/I (N=453)	With M184V/I (N=127)	<i>P</i> value	Without M184V/I (N= 466) [#]	With M184V/I (N=114) [#]
Follow-up* (days)	310 (95% CI: 292-328)	359 (95% CI: 320-398)	0.023	304 (95% CI: 284-325)	316 (95% CI: 261-371)
Age, years *	51.4 (95% CI: 50.4-52.4)	53.4 (95% CI: 51.7-55.1)	0.048	51.6 (95% CI: 49.0-54.1)	51.0 (95% CI: 43.1-59.0)
Sex, female	114 (25.2%)	38 (29.9%)	0.336	130 (27.9%)	37 (32.5%)
Body mass index, kg/m ² *	23.9 (95% CI: 23.3-24.6)	23.5 (95% CI: 22.8-24.3)	0.568	24.8 (95% CI: 23.5-26.2)	23.0 (95% CI: 18.5-27.5)
Time since documented HIV infection*(years)	15.0 (95% CI: 14.4-15.7)	20.6 (95% CI: 19.6-21.6)	<0.001	16.5 (95% CI: 15.0-17.9)	17.4 (95% CI: 15.4-19.4)
Time since antiretroviral therapy initiation*(years)	13.1 (95% CI: 12.6-13.7)	17.7 (95% CI: 16.9-18.6)	<0.001	14.3 (95% CI: 13.0-15.5)	15.5 (95% CI: 13.5-17.5)
Viral suppression before the	115.8	134.3	<0.001	122.4	128.2

switch to ABC/3TC/DTG* (months)	(95% CI: 110.6-121.0)	(95% CI: 126.5-142.1)		(95% CI: 112.2-132.7)	(95% CI: 108.1-148.3)
CD4 T-cell count nadir *(mm³)	195 (95% CI: 183-208)	176 (95% CI: 152-200)	0.151	187 (95% CI: 174-201)	174 (95% CI: 136-213)
CD4 T-cell count at the time of the switch to ABC/3TC/DTG* (mm ³)	647 (95% CI: 621-673)	665 (95% CI: 606-724)	0.578	669 (95% CI: 616-723)	694 (95% CI: 535-854)
Viral load before 1st ART regimen *(copies/ml, log ₁₀ transformed)	4.91 (95% CI: 4.82-5.01)	4.78 (95% CI: 4.53-5.02)	0.303	4.86 (95% CI: 4.77-4.96)	4.81 (95% CI: 4.54-5.07)
Prior AIDS diagnosis	101 (22.3%)	37 (29.1%)	0.086	112 (24.0%)	22 (19.3%)
At least 2 TAMs	41 (9.1%)	54 (42.5%)	<0.001	38 (8.2%)	5 (4.4%)
At least 3 TAMs	24 (5.3%)	40 (31.5%)	<0.001	27 (5.8%)	2 (1.8%)
Distribution of M184V/I by cohort:					
Aquitaine	51 (11.3%)	33 (26.0%)	<0.001	53 (11.4%)	20 (17.5%)
ARCA	26 (5.4%)	13 (10.2%)		35 (7.51%)	12 (10.5%)
ATHENA	100 (22.1%)	24 (18.9%)		98 (21.0%)	36 (31.6%)
ICONA	21 (4.6%)	5 (3.9%)		19 (4.1%)	5 (4.4%)
SHCS	255 (56.3%)	52 (40.9%)		261 (56.0%)	41 (36.0%)
Treatment class before the switch to ABC/3TC/DTG (at any time)					

NNRTI	318 (70.2%)	103 (81.1%)	0.020	327 (70.2%)	92 (80.7%)
INSTI	81 (17.9%)	24 (18.9%)	0.895	88 (18.9%)	22 (19.3%)
PI	417 (92.1%)	126 (99.2%)	0.007	437 (93.8%)	112 (98.2%)

Mean*, IPW: inverse probability weighting (analysis); CI: confidence interval; TAM: thymidine analogue mutations; NNRTI: non-nucleoside reverse transcriptase inhibitors; INSTI: integrase strand transfer inhibitors;

PI: protease inhibitor. In bold, all the confounders used in the multivariate logistic regression.

*Synthetic n values derived from weights. The mean of weights was 1.02 in the group without M184V/I and 0.89 in the group with M184V/I.

Accepted Manuscript

Table 4. Virological Primary Outcomes of Patients With or Without Archived M184V/I Mutations in the Subgroup Population (At Least One VF Before the Switch to ABC/3TC/DTG), Before and After Inverse Probability of Treatment Weighting Adjustment.

Outcomes	Primary Outcomes				
	Population with Prior VF Before IPW Adjustment			Population with Prior VF After IPW Adjustment	
	Without M184V/I (N=453)	With M184V/I (N=127)	p value	Without M184V/I (N= 466) [#]	With M184V/I (N=114) [#]
Virological failure (VF):	8 (1.8%)	4 (3.2%)	0.306	7 (1.5%)	3 (2.6%)
- 2x HIV-RNA >50 copies/mL	5	1		4	1
- 1x HIV-RNA >50 copies/mL + ABC/3TC/DTG stop	3	3		3	2
Treatment (ABC/3TC/DTG) discontinued for reasons other than VF	7 (17.22%)	13 (10.24%)	0.08	75 (16.1%)	20 (17.5%)

Virological blips (VB):					
- at least 1 VB during ABC/3TC/DTG treatment	22 (4.9%)	12 (9.5%)	0.083	23 (4.9%)	9 (7.9%)
- mean copies/ml (95% CI)	120 (63-177)	267 (-28-563)	0.303	117 (65-169)	307 (-157-772)
Incidence of VF per 1000 person-years	10.4 (0.21-20.60)	32.0 (0.64-63.4)	0.199	18.5 (4.8-32.3)	27.3 (-3.6-58.2)

#Synthetic n values derived from weights. The mean of weights was 1.02 in the group without M184V/I and 0.89 in the group with M184V/I.

IPW: inverse probability weighting (analysis).

Accepted Manuscript


Figure 1. Estimated probability of remaining free from VF with (blue) and without (red) the presence of the M184V/I mutation in the overall population (a; $p=0.295$) and in the subgroup population (at least one VF before the switch to ABC/3TC/DTG), before (b; $p= 0.781$) and after (c; $e=0.733$) inverse probability weighted adjustment.

Figure 2. Kaplan Meier plots showing probability of remaining free from VF or VB with (blue) and without (red) the presence of the M184V/I mutation in the overall population (a; $p=0.022$) and in the subgroup population (at least one VF before the switch to ABC/3TC/DTG), before (b; $p=0.106$) and after (c; $p=0.160$) inverse probability weighted analysis adjustment.

Accepted Manuscript


Figure 1

a




Accepted

B




C



Accepted Manuscript


Figure 2

A




Accepted

B



C



Accepted Manuscript